Factors Tied to COVID-19 Severity, Recovery, and Death in Cancer Patients
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
Home
COVID-19 Prognosis Improved Over Time for Cancer Patients
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
First-Line Advanced RCC Combo Tx Improves Outcomes Regardless of Prior Surgery
As first-line therapy for advanced renal cell carcinoma, nivolumab plus cabozantinib prolongs progression-free survival compared with sunitinib in patients with and without a prior nephrectomy.
Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
COVID-19 Has Killed More Americans Than the Spanish Flu Did in 1918
This happened despite vast gains in scientific knowledge during the past century.
Technology-Based Psychosocial Program Effective for Adolescent Leukemia Survivors
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Most Solid Tumor Patients Have ‘Adequate’ Response to COVID-19 Vaccination, Regardless of Treatment
Responses in cancer patients were noninferior to responses in patients without cancer.
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced Endometrial Cancer
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
‘Practice-Changing’ Results With Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO 2021
Loading... 
Loading...